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The emergence of the pandemic H1N1 strain of influenza in 2009 was associated with a unique w-shaped age-related
susceptibility curve, with higher incidence of morbidity and mortality among young persons and lower incidence among
older persons, also observed during the 1918 influenza pandemic. Pre-existing H1N1 antibodies were not cross-reactive
with the prior seasonal vaccine, forcing influenza experts to scramble to develop a new vaccine specific for the pandemic
virus. We hypothesized that response to T-cell epitopes that are cross-conserved between pandemic H1N1 and the
2008 seasonal influenza vaccine strains might have contributed to partial protection from clinical illness among older
adults, despite the lack of cross-reactive humoral immunity. Using immunoinformatics tools, we previously identified
hemagglutinin and neuraminidase epitopes that were highly conserved between seasonal and pandemic H1N1. Here,
we validated predicted CD4+ T-cell epitopes for their ability to bind HLA and to stimulate interferon-γ production in
peripheral blood mononuclear cells from a cohort of donors presenting with influenza-like illness during the 2009
pandemic and a separate cohort immunized with trivalent influenza vaccine in 2011. A limited-epitope heterologous
DNA-prime/peptide-boost vaccine composed of these sequences stimulated immune responses and lowered lung
viral loads in HLA DR3 transgenic mice challenged with pandemic 2009 H1N1 influenza. Cross-priming with conserved
influenza T-cell epitopes such as these may be critically important to T cell-mediated protection against pandemic H1N1
in the absence of cross-protective antibodies.

Introduction
As demonstrated by the 2009 H1N1 pandemic, novel influenza
viruses can spread rapidly when limited immunity exists within
the worldwide population. Due to the variability of influenza
virus strains from year to year, a new vaccine based on the circulating strains (and their HA and NA proteins) is made available
as often as every year, if necessary. These reformulated versions
of the seasonal influenza virus are not always protective, due to a
range of factors including genetic drift. There is an urgent need
to develop novel influenza vaccines that will provide more universal protection against influenza infection in a shorter time
frame than is currently feasible.
Because of the unique epidemiology of 2009 H1N1 influenza,
we hypothesized that T-cell responses to cross-reactive epitopes
might have contributed to diminished reports of influenza-like
illnesses and confirmed infection among older adults in the
absence of cross-reactive humoral immunity. There is considerable support for this hypothesis in published studies involving
exposure or vaccination and heterotypic challenge in animal

models.1-4 One explanation for the unusual age distribution
is that, similar to the 1918 epidemic and again as occurred in
1977,5,6 older individuals might have established a cross-reactive
cell-mediated immune response to novel H1N1 due to having
been vaccinated or exposed to circulating influenza H1N1.7
While cross-reactive T-cell responses (in the absence of a crossreactive humoral immune response) may not have provided complete protection against infection, it is possible that the severity
of the illness was reduced, leading to a lower hospitalization rate
and lower reports of H1N1 in this age group, as was observed in
a case-control study from Mexico.8
We previously performed an immunoinformatics analysis
to define cross-conserved HA and NA CD4 + T-cell epitopes
between the emerging pandemic strain and the prior seasonal
influenza vaccine strains, using the A/California/04/2009
sequence as a departure point. The analysis was performed in
March 2009, immediately following publication of the virus
sequence.9,10 Here we present results from in vitro studies confirming these predictions. The cross-conserved epitopes bound to
multiple HLA and were antigenic in recall assays using peripheral
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Figure 1. HLA DR binding affinities for immunoinformatic-predicted H1N1 influenza cross-conserved epitopes. Peptide identifiers and sequences
are noted in the first and second columns, respectively. IC50 values in μM units were calculated from curves fitted to dose-dependence competition
binding data for each peptide-HLA DR allele pair. Peptide binding affinity is shown according to the following classification: IC50 < 1 μM (black), 1 μM <
IC50 < 10 μM (dark gray), 10 μM < IC50 < 50 μM (gray), 50 μM < IC50 < 100 μM (light gray), IC50 > 100 μM (lightest gray). IC50 values too high to accurately
measure under binding conditions tested are considered non-binders (NB; shown in white cells).

blood mononuclear cells (PBMCs) from a patient presenting with
influenza-like illness during the recent pandemic and in a cohort
of 2011 trivalent influenza virus (TIV) vaccines. Vaccination
with cross-conserved influenza epitopes stimulated de novo
T-cell responses that lower viral burden in HLA transgenic mice,
despite an absence of vaccine-induced antibodies. These studies appear to support the hypothesis that cross-protective T-cell
responses might have played a role in reducing influenza morbidity and mortality in humans.
Results
HLA binding properties of cross-conserved H1N1 influenza
epitopes. In a previous study, we identified peptide sequences
from 2008–2009 influenza A seasonal vaccine HA and NA
antigens that are cross-conserved with the corresponding antigens from 2009 pandemic H1N1 and potentially immunogenic,
using the EpiMatrix T cell epitope mapping algorithm.9 These
sequences were assayed in vitro for their capacity to bind multiple
HLA types, including DRB1*0101, DRB1*0301, DRB1*0401,
DRB1*0701, DRB1*1101, and DRB1*1501. Ninety percent of
the peptides bound as predicted to at least 3 HLA alleles, 70%
to at least 4 HLA alleles, 60% to at least 5, and 10% to all
6. Surprisingly, peptide HA_112–129 did not bind any HLA
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despite immunoinformatic predictions it would bind all assayed
alleles except DRB1*0701. In our experience testing thousands
of peptides predicted to bind HLA, this is a singularly unusual
finding. It may be explained by self-association, which would
interfere with HLA interactions no matter what allele is assayed.
Given this highly unusual result, we exclude the peptide from
the following summary of binding results for the group of
peptides.
Of the 54 peptide-HLA binding interactions assayed, 18.5%
were very high affinity, 22.2% high affinity, 22.2% moderate affinity, 9.3% low affinity, 1.9% very low affinity, and no
measurable affinity was observed for 25.9% (Fig. 1). The concordance of computational predictions and binding assay results
was evaluated with classification of peptide-HLA binding pairs
as either true positive, false positive, true negative, or false negative. A non-binder was defined as a confirmed true negative prediction if the peptide had an EpiMatrix Z-score that was lower
than the defined cut-off (1.64) for its associated HLA allele.
Positive predictions were defined as epitopes scoring ≥1.64 on the
EpiMatrix Z-scale and binding HLA at any affinity. Overall, the
concordance with predictions (both positive and negative) was
76%. With respect to each allele assayed, the values are 78% for
DRB1*0101, 89% for DRB1*0301, 67% for DRB1*0401, 78%
for DRB1*0701, 89% for DRB1*1101, and 56% for DRB1*1501.
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These HLA-binding and epitope prediction results are consistent
with previously published studies using the same algorithms and
assay conditions.11
Epitope-specific IFNγ responses: Acute ILI subjects. Ex vivo
IFNγ ELISpot assays were performed using PBMCs from six
patients ages 18 to 65 y old, who were admitted to the Rhode Island
Hospital with influenza-like illness between November 2009 and
February 2010 (Table 1). RT-PCR detection of influenza in nasal
washes confirmed pandemic H1N1 infection in one subject and
no influenza infection in the others. ELISpot responses were considered positive when (1) the number of IFNγ spot-forming cells
exceeded 50 per million PBMCs cultured, (2) spot counts were
at least twice background, and (3) spot counts were statistically
different from “no stimulus” measurements (P < 0.05). In the one
pandemic H1N1 case, significant influenza-specific IFNγ recall
responses were observed when PBMCs were stimulated ex vivo
with a pool of epitope peptides and with individual peptides in an
ELISpot assay (Fig. 2). No peptide-specific ex vivo interferon-γ
(IFNγ) responses were detected in PBMC samples taken from
the five other subjects (data not shown). Although three of these
subjects received the 2008–2009 TIV vaccine, the absence of an
ex vivo response was not unexpected as we previously found that
vaccine-specific T cells are found at low frequency and a period of
expansion in culture is required to detect them.11

Table 1. Characteristics of cohort presenting with ILI during 2009 H1N1
pandemic
Patient
ID

Seasonal
vaccine
2009–2010

Seasonal
vaccine
2008–2009

Viral infection

Ex vivo
T-Cell
response

EP1

Yes

Yes

None

No

EP2

No

No

Adenovirus

No

EP3

No

No

None

No
No

1_0103

No

Yes

None

1_0104

No

Yes

None

No

1_0107

No

No

H1N1

Yes

Column headers: human subject ID code; vaccination status in 2008–
2009 and 2009–2010 influenza seasons; viral diagnostic assay result; ex
vivo IFNγ ELISpot response.

Epitope-specific IFNγ responses: 2011 TIV-immunized
subjects. To better determine the antigenic potential of crossconserved H1N1 peptides, we expanded low frequency influenza-specific T cells over a nine-day period using PBMC samples
collected before and three weeks following 2011 TIV vaccination
of 16 young and elderly adult subjects. Cells were expanded by
stimulation with a pool of HA and NA cross-conserved peptides
and then re-stimulated with pooled or individual peptides for

Figure 2. Ex vivo human IFNγ responses elicited by cross-conserved epitopes in H1N1 influenza infection. Cross-conserved epitopes were assayed for
T cell reactivity by IFNγ ELISpot assay, using PBMCs isolated from patients that presented with influenza-like illness at Rhode Island Hospital. Data from
the only H1N1 influenza-positive subject are presented. ELISpot responses were considered positive if three criteria were met: (1) spot-forming cells
(SFC) per million PBMCs were at least 50 over background; (2) SFC per million PBMCs were at least 2-fold over background; and (3) antigen-stimulated
SFC numbers were statistically different (Student’s t-test; *p < 0.05, **p < 0.01) from non-stimulated counts. Data are the mean SFC over background
per million PBMCs that secrete IFNγ in response to individual and pooled influenza HA and NA cross-conserved epitopes are presented. The 50 SFC
over background per million PBMCs cutoff is denoted by the dotted line.
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Figure 3. Antigen-specific human IFNγ responses elicited by cross-conserved epitopes before and after 2010–2011 TIV vaccination. Cross-conserved
epitopes were assayed for T cell reactivity by cultured IFNγ ELISpot assay using PBMCs isolated from normal human donors before and three weeks
after TIV vaccination (n = 16). Assays were performed following a nine-day T cell expansion after stimulation with cross-conserved influenza epitopes.
The numbers of SFC over background per million PBMCs that secrete IFNγ in response to individual and pooled influenza HA and NA cross-conserved
epitopes are presented. Individual subject average responses are represented by dots and the average response across subjects by white bars. The 50
SFC over background per million PBMCs cutoff is denoted by the dotted line.

measurement of IFNγ production by ELISpot assay. All subjects
responded to the pool of cross-conserved peptides post-immunization by the criteria for a positive ELISpot response described
above, apart from two subjects, one of which nearly met all
three criteria (Fig. 3; Table S1). Two additional subjects did not
respond prior to immunization but significant responses were
observed in the group overall, suggesting that T-cell precursors
for this set of epitopes do exist. The average spot forming cell
count following T-cell expansion did not significantly increase
post-immunization.
In individual peptide stimulations, eight out of ten (80%) epitopes stimulated IFNγ production greater than 50 spot forming
cells per million PBMCs prior to immunization and vaccination
boosted these epitope-specific responses. Differences between
pre- and post-immunization IFNγ production were not significant by the Wilcoxon matched-pairs signed rank test, except for
HA_456–480 (P < 0.05). While we expected to observe significant differences between these time points, it is very likely that
they were lost in the course of in vitro expansion and that stimulation at a lower peptide concentration would preserve differences.
Two peptides (HA_38–61 and HA_112–129) stimulated no
significant responses in any subjects. The small cohort size of
the study with limited HLA diversity may explain this result.
Alternatively, these sequences may stimulate type 1 helper T cell
cytokines other than IFNγ, such as interleukin-2 and tumor
necrosis α. Thus, positive responses may be observed in a larger
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cohort with broader HLA coverage, comparing multiple cytokine responses. Notably, while both these peptides stimulated no
IFNγ response among vaccinated subjects even after a period of
T-cell expansion, robust ex vivo responses were observed in the
one subject infected during the 2009 pandemic (Fig. 2). While
trends, let alone conclusions, cannot be drawn from a single subject, we can speculate that live virus infection stimulates different
T cell specificities than TIV vaccination.
Multi-epitope DNA vaccine construction. Following in vitro
antigenicity testing, we set out to evaluate the in vivo immunogenicity of cross-conserved H1N1 influenza epitopes using a
heterologous DNA-prime/peptide-boost vaccination strategy. To
design the DNA vaccine, epitope sequences were initially joined
end to end in a random order. To avoid production of neo-epitopes
at epitope junctions, the VaccineCAD algorithm was used to rearrange epitopes in an order that diminishes potential junctional
immunogenicity. This algorithm iteratively rearranges strings of
epitopes while assessing junctional immunogenicity, prioritizing
those sequences that contain the fewest junctional epitopes. The
default order contained significant predicted immunogenicity at
a single junction (EpiMatrix score ~10). Re-ordering of epitopes
by VaccineCAD yielded a sequence with minimized junctional
immunogenicity (EpiMatrix scores < −3), well below the threshold for potential immunogenicity.
Immunogenicity and efficacy of cross-conserved H1N1
influenza epitopes. We evaluated the cross-conserved H1N1
influenza epitopes for immunogenicity and efficacy in HLA
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DR3 transgenic mice. The HLA transgenic mouse model represents an
improvement over wild-type mice (and
other animal models), because animal
and human MHC present different T-cell
epitopes.12 MHC class II-mediated cellular immunity in the mouse MHC II
knockout, HLA DR3 knock-in strain is
completely restricted by human HLA and
not by mouse MHC.13 Mice were injected
intramuscularly with the DNA vaccine
delivered by electroporation, three times,
over two-week intervals. Two weeks later,
they were boosted twice subcutaneously
with corresponding epitope peptides formulated in incomplete Freund’s adjuvant
(IFA), with immunostimulatory CpG
ODN 1826, CL097 and muramyl dipeptide adjuvants, over a two-week interval.
A control group of mice received empty
vector in the DNA-prime phase and peptide-free IFA emulsion in the boost phase.
Figure 4. Cell-mediated response to immunization of HLA DR3 transgenic mice with crossThree weeks following the final immuconserved H1N1 influenza class II HLA epitopes. Mice were primed with plasmid DNA vaccine
nization, splenocytes were isolated to
and boosted with peptides comprising cross-conserved H1N1 influenza class II HLA epitopes or
measure T-cell responses to individual
vaccine vehicle containing no epitopes. Epitope-specific cellular responses in splenocyte cultures
epitopes from individual mice by IFNγ
for individual and pooled epitopes were measured by IFNγ ELISpot assay. Data are the mean spot
forming cells (SFC) per million splenocytes ± standard deviation derived for 6 mice treated comELISpot assay (n = 6/group). ELISpot
parably. Individual epitope and pooled epitope responses in vaccinated mice showing statistical
responses were considered positive accordsignificance (Student’s t-test) when compared with controls are indicated: *p < 0.05. A solid line
ing to the same criteria used in human
denotes the 50 SFC over background per million splenocytes cutoff.
studies described above. Immunization of
DR3 transgenic mice stimulated statistically significant (Student t-test, P < 0.01) T-cell responses to the measured by plaque assay differed significantly between the two
pool of epitopes and to two out of 10 individual epitopes (20%): groups four days post-infection (Student t-test, P < 0.01). Lung
HA_321–341 and HA_456–480 (Fig. 4). Out of the 10 epitopes viral titers were 70% lower in immunized mice four days followevaluated, seven are predicted to bind HLA DR39 ; thus, two out ing infection; no significant difference was observed two days
of seven (29%) are true positive epitopes. By more relaxed criteria, prior (Fig. 5). Notably, as vaccine-induced antibodies specific
epitopes HA_38–61 and HA_432–453 may also be considered for neither whole HA antigen nor the peptide immunogens was
positive as they stimulate responses that are >20 SFC per mil- observed by ELISA (data not shown), efficacy was apparently
lion splenocytes, > 2 × background and statistically distinct from cell-mediated only. Thus, we conclude that this minimal-epitope
background. Both these sequences are predicted to bind HLA based H1N1 influenza epitope-based vaccine is immunogenic
DR3, thus raising the number of immunogenic epitopes to 40% and partially efficacious.
of those tested and 57% positively predicted sequences. Three of
the ten epitopes (HA_319–345, HA_396–417, HA_548–563)
Discussion
are not predicted to bind HLA DR3 and were not immunogenic in this study. In sum, seven out of 10 (70%) of immune Leading up to the present study, we used EpiMatrix, a T-cell epiresponses measured are in concordance with the immunoinfor- tope prediction and sequence comparison tool, to discover crossmatic predictions.
conserved putative T-cell epitope sequences among the three
Next, we set out to evaluate vaccine efficacy against A/ hemagglutinin (HA) and neuraminidase (NA) proteins conCalifornia/07/2009 challenge in DR3 transgenic mice. Three tained in 2008–2009 TIV and their counterparts in pandemic
weeks following the final immunization, 16 mice in each group 2009 H1N1 influenza virus (A/California/04/2009).9 We found
were challenged intranasally with 106 PFU of virus. Mice in both greater than 50% conservation of helper T and CTL epitopes
groups became ill and lost >20% of their pre-challenge weight by between A/California/04/2009 and TIV HA for “supertype”
day 7 post-infection and were sacrificed. While it was not surpris- HLA alleles, whereas conservation was lower among NA epiting that there was no difference in morbidity between immunized opes. A total of 16 promiscuous helper T-cell epitopes are conand naïve mice, as only two to four epitopes were immunogenic, tained in the A/California/04/2009 HA sequence, of which nine
we did detect differences in lung viral titers. Viral burden as (56%) were 100% conserved in the 2008–2009 influenza vaccine
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Figure 5. Epitope-driven vaccine reduces lung viral titers in pandemic
H1N1 influenza infection of HLA DR3 transgenic mice. Mice that were
primed with plasmid DNA vaccine and boosted with peptides comprising cross-conserved H1N1 influenza class II HLA epitopes or vaccine
vehicle containing no epitopes were infected with 106 PFU A/California/07/2009. Data are the viral burden of four mice from each group at
two and four days post-infection as determined by viral plaque assay.
Individual titers are denoted by filled dots and average titers by horizontal lines. Titers in vaccinated mice showing statistical significance
(Student t-test) when compared with controls are indicated: **p < 0.01.

strain H1N1 HA; 81% were either identical or had one conservative amino acid substitution. Similarly, 50% of predicted CTL
epitopes found in A/California/04/2009 HA also were found
in TIV HA sequences.3 Here, we confirmed immunoinformatic
predictions in experiments designed to evaluate the capacity of
the nine highest conserved helper T cell HA epitopes and the
most conserved NA epitope to bind HLA and stimulate immune
recall and de novo T-cell responses.
Recognition of the cross-conserved epitopes by HLA and
their immunoreactivity in exposed and in vaccinated subjects
demonstrated in this study does not imply that they are necessarily protective sequences. Rather, it confirms the existence of
cross-conserved T cells and suggests that further evaluation of
the contributions of these cross-conserved epitopes to protection
against infection, morbidity and mortality in the next pandemic,
should one occur, would be entirely worthwhile. This is further supported by the vaccination and challenge study reported
here. Despite the fact that immunized mice had a very restricted
immune response (2 to 4 of 7 potential epitopes were immunogenic), reduced viral titers were observed. Our selection of HA
and NA epitopes only for this study was based on our interest
in determining whether cross-conserved T-cell responses to the
proteins usually contained in seasonal influenza vaccine would
protect against challenge. However, it is well known that conventional egg-based vaccine production results in a product that
contains other influenza proteins. Immune response to residual
internal proteins, which are highly cross-conserved between
influenza strains, has been described.14 HLA restriction of this
animal model limited the number of epitopes that were potentially immunogenic as only two to four of seven induced T-cell
response following vaccination. Had additional epitopes from
internal proteins been included in this minimal epitope-based
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vaccine, greater protection against viral challenge may have been
observed using this vaccine strategy, as internal antigens are well
known to be cross-reactive in humans and animal models.15,16
This study is consistent with others showing that, in the
absence of antibody responses, cellular immune response can
provide effective protective immunity in animal models.17-19 With
respect to pH1N1 infection, two independent studies demonstrated CTLs and CD4 + T cells raised against the seasonal H1N1
viruses, A/Brisbane/59/2007 and A/New Caledonia/20/99,
respectively, were capable of responding against whole protein
antigens from the pH1N1 virus.20,21 In addition, cross-reactive human T helper cell responses were observed for defined
HLA-DR4 epitopes.22 Moreover, ferrets immunized with prepandemic seasonal TIV were protected from influenza disease,
though they lacked sterilizing immunity against pH1N1 infection.23 These studies suggest that when antibodies may be unable
to protect against variant virus challenge, T cells responding to
conserved epitopes may act to mitigate disease severity. Putting
the existing data on murine challenge and the current validation
of cross-conserved epitopes into the human context, we would
expect that priming with similar cross-conserved or “universal”
influenza vaccine epitopes might improve the immune response
to conventional influenza vaccines to provide enhanced protection against subsequent challenge. A number of “universal influenza vaccines” based on the idea that cross-conserved B-cell
epitopes are currently in development 24-26 ; here we show that
cross-conserved T-cell epitopes should also be given serious consideration in vaccine design.
This study confirmed the immunogenicity of cross-reactive T-cell epitopes; a similar study performed with pandemic
H1N1-naïve individuals also confirmed the antigenicity of the
epitopes.27 We do not presuppose that the T-cell epitopes will be
sufficient; instead, it will be important to the field to determine
if expanding T-cell response to cross-reactive epitopes results in
a degree of cross-protection. The finding that T-cell responses
to an extremely limited number (two to four) of cross-reactive
epitopes may have the capacity to attenuate the course of novel
H1N1-induced disease, in the absence of cross-reactive antibody
response, may also lead to development of alternative approaches
to “priming” immune responses and to improved means of limiting future flu pandemics, through the use of vaccines that diminish the number of individuals who develop clinical symptoms
following infection.
Methods
Peptide synthesis. Peptides were synthesized using 9-fluoronylmethoxy-carbonyl (Fmoc) chemistry at 21st Century
Biochemicals. Peptide purity was >80% as ascertained by analytical reversed phase HPLC. Peptide mass was confirmed by
tandem mass spectrometry.
HLA binding. Peptides were assayed for HLA affinity in a
competition binding assay based on Steere et al.28 In 96-well
plates, a test peptide and a reference peptide compete for binding to a purified class II HLA molecule (Benaroya Research
Institute) for 24 h at 37 °C. Non-biotinylated test peptides were
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evaluated over a wide range of concentrations (0.01–200 μM)
while biotinylated standard peptide was held at a fixed concentration (0.1 μM). Peptide-class II HLA complexes were then captured on ELISA plates using pan anti-HLA-DR antibody (L243,
BioXCell). Plates were washed and incubated with Europiumlabeled streptavidin (Perkin-Elmer) for one hour at room temperature. Europium activation buffer was added to develop the
plates for 15–20 min at room temperature before they were read
on a Time Resolved Fluorescence (TRF) plate reader. All assays
were performed in triplicate. Dose dependence curves were generated by fitting data using the four-parameter logistic equation,
and IC50 values were calculated in SigmaPlot 11.0 (Systat). Based
on the IC50 values, peptide binding to a given HLA allele was
classified as very high affinity (<1 μM), high affinity (1–10 μM),
moderate affinity (10–50 μM), low affinity (50–100 μM), or
very low affinity (>100 μM). Peptides that did not inhibit the
binding of the biotinylated reference peptide at any concentration
were considered non-binders. Binding assays were performed for
six alleles: DRB1*0101, DRB1*0301, DRB1*0401, DRB1*0701,
DRB1*1101, and DRB1*1501, providing a broad representation
of class II HLA allele binding pockets.29
PBMC collection, culture and characterization. Acute influenza-like illness (ILI) subjects. During the 2009–2010 influenza
season, patients who presented to the emergency department
at Rhode Island Hospital with acute influenza-like symptoms
(defined as a fever combined with a cough) were recruited for
enrollment. Six acute ILI study subjects between the ages of 18
and 65 were recruited and gave their consent to participate in
the study (Lifespan IRB protocol 4074–08). Nasal washings
were tested using reverse transcriptase polymerase chain reaction (RT PCR) for determination of influenza subtype. Blood
samples were obtained and PBMCs were separated from whole
blood by Ficoll density gradient centrifugation and PBMCs were
resuspended in human R-10 media (RPMI + Glutamax-88%,
Heat inactivated human AB serum-1%, L-Glutamine-<1%,
Gentamycin-<1%). For all subjects, enzyme-linked immunospot
(ELISpot) assays were performed ex vivo. Donor HLA class II
types were determined using the One Lambda Micro SSPTM
High Resolution HLA class II kit at the Hartford Hospital
Transplant Immunology Laboratory. Human subject studies
were performed in accordance with NIH regulations and with
the approval of the Lifespan and Ethical and Independent Review
Services institutional review boards.
2011 TIV-immunized subjects. Frozen PBMCs donated by 18
healthy adults (ages 22–77 y), before and three weeks after 2011
TIV immunization, were generously provided by VaxDesign. If
applicable, the date of previous vaccination (prior to donation) was
provided for each donor. T cell assays were performed following a
period of culture to allow for expansion of antigen-specific T cells.
Thawed whole PBMC populations were rested overnight and then
stimulated with peptide antigen over nine days at 37 °C under a
5% CO2 atmosphere. In a 48-well plate, 5 × 106 cells in 150 μl
Iscove’s Modified Dulbecco’s Medium (IMDM) were stimulated
with a pool of HA and NA peptides at 10 μg/ml on Day 1. Three
days later, IL-2 was added to 10 ng/ml and the culture volume
raised to 300 μl. On Day 7, cells were supplemented with 10 ng/
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ml IL-2 by half media replacement. Finally, 2 days later, PBMCs
were collected and washed in preparation for antigen re-stimulation to measure cytokine secretion by enzyme-linked immunospot
(ELISpot) assay. Due to low cell recovery from two subjects,
ELISpot assays were only performed on 16 of the 18 PBMC samples. Donor HLA class II types were determined using the One
Lambda Micro SSPTM High Resolution HLA class II kit at the
Hartford Hospital Transplant Immunology Laboratory. Human
subject studies were performed in accordance with NIH regulations and with the approval of the Ethical and Independent Review
Services institutional review board.
ELISpot assay. The frequency of epitope-specific PBMCs was
determined by IFNγ ELISpot assay using the Mabtech IFNγ
ELISpot Kit according to the manufacturer’s protocol. Washed
PBMCs were added at 2.5 × 105 cells per well to 96-well plates precoated with anti-IFNγ antibody. Individual peptides were added
at 10 μg/ml in triplicate wells. The pool of HA and NA peptides was added at 10 μg/ml, or 1 μg/ml per peptide. Triplicate
wells were plated with PHA (2 μg/ml) as a positive control, and
6 wells with no peptide were used for background determination. Raw spot counts were recorded by ZellNet Consulting, Inc.
using a Zeiss high-resolution automated ELISpot reader system
and companion KS ELISpot software. Results were calculated
as the average number of spots in the peptide wells, adjusted to
spots per one million cells. A response was considered peptidespecific if the number of spots was at least twice background,
greater than 50 spot forming cells per well (1 response per 20 000
PBMCs), and statistically different (P < 0.05) from that of the
control wells by the Student t-test. ELISpot assays using splenic
leukocytes from immunized mice were similarly performed using
mouse IFNγ-specific reagents.
Multi-epitope DNA vaccine engineering. Epitope sequences
were concatenated to form a multi-epitope gene containing 10
HLA class II epitopes. Epitopes were assembled in a random
sequence at first and then re-ordered to avoid creation of novel
epitopes at epitope junctions using the VaccineCAD algorithm.30
No spacer sequences were required for insertion at epitope junctions to eliminate junctional immunogenicity. A histidine tag
was incorporated downstream of the epitope sequences followed
by two stop codons.
Genes were synthesized by GeneArt and subcloned at predetermined flanking restriction sites downstream of the tissue
plasminogen activator leader sequence in pNTC8682-eRNA41H
(Nature Technology Corporation), a DNA vaccine vector that
accommodates FDA recommendations for construction of plasmid DNA vaccines.31
Plasmid DNA vaccine production. High purity plasmid for
immunizations was prepared by Nature Technology Corporation,
Inc. at research grade. Each plasmid underwent quality control
testing including spectrophotometric concentration and A 260 /
A 280 ratio determination (1.97), restriction digest analysis to
assure the presence of the multi-epitope genes, agarose gel electrophoresis determination of residual host RNA and DNA (none
detected), and quantitative endotoxin testing (<2.0 EU/mg).
Peptide vaccine preparation. Peptides corresponding to
epitopes in the DNA vaccine were formulated in incomplete
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Freund’s adjuvant (IFA) with 10 μg each of immunostimulatory CpG oligodeoxynucleotide 1826 (5'-TCCATGACGT
TCCTGACGTT-3'), muramyl dipeptide (MDP) and CL097
(InvivoGen).
Mice. HLA DR3 transgenic mice were obtained from Dr.
Chella David (Mayo Medical School) under commercial license.
The mice express the HLA DR3α and β genes on a B.10-Ab0
mouse class II-negative background.13 Experiments were conducted with mice 6 to 10 weeks old at the point of initiation.
All studies were performed in full compliance with the standards
of the TGA Sciences, Inc. Institutional Animal Care and Use
Committee and in accordance with NIH publications entitled
“Principles for Use of Animals” and “Guide for the Care and Use
of Laboratory Animals.”
Vaccinations. Vaccine and placebo-treated mice (n = 22/
group) were all female and 6–8 weeks old at the start of immunizations. DNA-prime vaccine was administered to mice intramuscularly by electroporation using the Ichor Medical Systems
with 20 μL of 10 μg naked DNA in sterile PBS injected into
the quadriceps muscle. For peptide-boost immunizations, each
mouse was anesthetized with ketamine/xylazine and administered 100 μl IFA emulsion (50 μg peptide) subcutaneously by
needle stick injection.
Virus preparation. Stocks of influenza A/California/07/2009
virus were propagated in the allantoic cavity of 9- to 11-d-old
embryonated specific pathogen-free (SPF) hen’s eggs at 37 °C.
The allantoic fluids from eggs inoculated with each virus was
harvested 24 h post-inoculation and tested for hemagglutinating
activity. Eggs inoculated with viruses were incubated at 33 °C
and were harvested 3 d post-inoculation. Infectious allantoic fluids were pooled, divided into aliquots, and stored at −80 °C until
used for studies. The viral titer was determined by serial titration
in Madin-Darby canine kidney (MDCK) cells and calculated by
the method developed by Reed and Muench.32 Virus preparation
was conducted using enhanced BSL-2 containment procedures
in laboratories approved for use by the USDA and Centers for
Disease Control and Prevention.
Respiratory challenge. Mice were dosed with 1 × 106 PFU
A/California/07/2009 intranasally under ketamine/xylazine
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